Diamyd Medical provides an update on strategic review and financial position
Diamyd Medical today announces that the initial phase of the strategic review, initiated following the discontinuation of the Phase 3 DIAGNODE-3 trial, has been completed. Strategic review updateThe initial review phase has resulted in the identification of a short list of potential counterparties, and the Company will now proceed with a focused evaluation of these. As part of the review, Diamyd Medical is also evaluating strategic alternatives for its biomanufacturing facility in Umeå including potential stand-alone opportunities, or a divestment. With respect to retogatein (